Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15676054 | 1.00 | GRM5 (0.45) | GRM5CA2CYP2D6CYP1A2CYP2C9 | |
| SCHEMBL19795865 | 0.86 | LMNA (0.39) | GRM5CYP2D6MAPTALDH1A1 | |
| SCHEMBL19803721 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6KDM4EPOLB | |
| SCHEMBL15676298 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6 | |
| SCHEMBL19061962 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6 | |
| SCHEMBL19795866 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6 | |
| SCHEMBL15676299 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6 | |
| SCHEMBL15699098 | 0.84 | GRM5 (0.44) | GRM5CA2CYP2D6 | |
| SCHEMBL15675996 | 0.82 | ALDH1A1 (0.41) | GRM5CYP2D6KDM4EPOLBMAPT | |
| SCHEMBL17966098 | 0.82 | ALDH1A1 (0.41) | GRM5CYP2D6KDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202340-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022697-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | GBA1, GBA2, GAA | GRM5 4103/4885CA2 1735/4885CYP2D6 3646/4885 |
| US-10202340-B2 | Glucosylceramide synthase inhibitors and therapeutic methods using the same | GBA1, GBA2, GAA | GRM5 4103/4885CA2 1735/4885CYP2D6 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.